BIODESIX INC
For the period ended Nov 5, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Nov 5, 2026 · Filed Nov 5, 2026
Use the contents to explore the available documents and sections.
BDSX$8.53-57.0%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · (in thousands, except share data)
(in thousands, except share data)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $28,409 | $18,987 |
| Accounts receivable, net of allowance for credit losses of $121 and $62 | 9,117 | 9,036 |
| Other current assets | 4,609 | 4,495 |
| Total current assets | 42,135 | 32,518 |
| Non‑current assets | ||
| Property and equipment, net | 23,616 | 24,817 |
| Intangible assets, net | 2,531 | 3,883 |
| Operating lease right-of-use assets | 4,334 | 2,997 |
| Goodwill | 15,031 | 15,031 |
| Other long-term assets | 6,297 | 8,230 |
| Total non‑current assets | 51,809 | 54,958 |
| Total assets | $93,944 | $87,476 |
| Liabilities and Stockholders' Equity (Deficit) | ||
| Current liabilities | ||
| Accounts payable | $2,626 | $3,080 |
| Accrued liabilities | 8,505 | 11,033 |
| Deferred revenue | 360 | 961 |
| Current portion of operating lease liabilities | 2,201 | 1,364 |
| Current portion of notes payable | — | 6 |
| Other current liabilities | 556 | 992 |
| Total current liabilities | 14,248 | 17,436 |
| Non‑current liabilities | ||
| Long‑term notes payable, net of current portion | 47,146 | 47,445 |
| Long-term operating lease liabilities | 23,093 | 24,039 |
| Other long-term liabilities | 782 | 1,021 |
| Total non‑current liabilities | 71,021 | 72,505 |
| Total liabilities | 85,269 | 89,941 |
| Commitments and contingencies | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2026 and 2025) issued and outstanding | — | — |
| Common stock, $0.001 par value, 200,000,000 authorized; 11,054,674 (2026) and 8,253,053 (2025) shares issued and outstanding | 11 | 8 |
| Additional paid‑in capital | 529,524 | 495,289 |
| Accumulated deficit | (520,860) | (497,762) |
| Total stockholders’ equity (deficit) | 8,675 | (2,465) |
| Total liabilities and stockholders’ equity (deficit) | $93,944 | $87,476 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.